B cell lymphoma DNA vaccine - Vical

Drug Profile

B cell lymphoma DNA vaccine - Vical

Alternative Names: Vaxid

Latest Information Update: 04 Nov 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Stanford University; Vical
  • Class Cancer vaccines; DNA vaccines; Gene therapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Lymphoma

Most Recent Events

  • 30 Nov 2001 Discontinued-Phase II for Lymphoma in USA (IM)
  • 18 Aug 1998 Phase-II clinical trials for Lymphoma in USA (IM)
  • 04 Nov 1996 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top